Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)

BACKGROUND: Simvastatin, 20 mg, plus ezetimibe, 10 mg, daily (simvastatin plus ezetimibe) reduced major atherosclerotic events in patients with moderate to severe chronic kidney disease (CKD) in the Study of Heart and Renal Protection (SHARP), but its cost-effectiveness is unknown. STUDY DESIGN: Cos...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Am J Kidney Dis
Auteurs principaux: Mihaylova, Borislava, Schlackow, Iryna, Herrington, William, Lozano-Kühne, Jingky, Kent, Seamus, Emberson, Jonathan, Reith, Christina, Haynes, Richard, Cass, Alan, Craig, Jonathan, Gray, Alastair, Collins, Rory, Landray, Martin J., Baigent, Colin
Format: Artigo
Langue:Inglês
Publié: W.B. Saunders 2016
Sujets:
Original Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4801501/
https://ncbi.nlm.nih.gov/pubmed/26597925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.ajkd.2015.09.020
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires